Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EntreMed has received results from a preclinical study evaluating its lead compound, 2-methoxyestradiol, which show the drug to effectively treat joint inflammation and damage.
Subscribe to our email newsletter
The data from preclinical studies in a rat collagen-induced arthritis model of chronic autoimmune inflammatory joint disease demonstrated that daily oral administration of 2-methoxyestradiol (2ME2) resulted in a statistically significant reduction in clinical severity of joint inflammation and inhibition of articular joint damage as determined by high resolution radiographs of bone erosions.
The company believes these findings further support the potential for 2ME2 as a disease modifying anti- rheumatic drug. The anti-arthritic activities of 2ME2 were apparent in both preventive (prior to arthritis onset) and treatment studies (active arthritis). In addition, when 2ME2 was administered in the preventive setting, the onset of arthritis was delayed significantly. The beneficial effects of 2ME2 were dose-dependent and non-immunosuppressive.
EntreMed now hopes to start studies that would allow the company to make an investigational new drug application to the FDA in 2006.